Mersana Therapeutics diskutieren
Mersana Therapeutics
WKN: A2DTR7 / Symbol: MRSN / Name: Mersana Therapeutics / Aktie / Small Cap /
0,26 €
-4,53 %
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $10.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock, up previously from $1.00.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $7.00.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $4.00.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $5.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target raised by analysts at Truist Financial Co. from $9.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "buy" rating re-affirmed by analysts at BTIG Research.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Guggenheim from $125.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Truist Financial Corporation from $250.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for MRSN provided by MarketBeat
Neueste Beiträge
StockNews_com in BGSF Inc. diskutieren